Actor portrayal
Actor portrayal
Clearance Rates
RAPID, RELIABLE RESULTS ANYWHERE FOR PLAQUE PSORIASIS
POWERFUL SKIN CLEARANCE AT WEEK 8
See the results at Week 8
Primary
Endpoint
IGA Success
Key Secondary
Endpoint
I-IGA Success
% of patients achieving IGA Success
Data are pooled analyses of the DERMIS-1 and DERMIS-2 studies.
IGA Success rates at Week 8 were consistent regardless of baseline BSA involvement
(mild, moderate, severe)7
% of patients achieving I-IGA Success
70% of patients achieved I-IGA Success at Week 81,2
Data are pooled analyses of the DERMIS-1 and DERMIS-2 studies.
3 out of 4 patients achieved Clear or Almost Clear
skin in intertriginous areas with ZORYVE (75%, n=116)
vs vehicle (23%, n=63)7
Nearly all patients had IMPROVED CLINICAL SIGNS with ZORYVE8
9 out of 10 (95%) had any PASI improvement at Week 8 vs 71% with vehicle
40% achieved PASI-75 at Week 8 vs 7% with vehicle
12% achieved PASI-100 (complete response) at Week 8 vs 1% with vehicle
Pooled PASI response rates (N=881). Analysis provides a summary of PASI improvement for every patient in DERMIS-1 and DERMIS-2. PASI response rates are defined as percentage of patients with improved PASI scores from baseline to Week 8. PASI scores evaluate the following plaque psoriasis symptoms: erythema, skin thickness (induration), and desquamation (scaling). BSA = Body Surface Area. IGA = Investigator Global Assessment. I-IGA = Intertriginous Investigator Global Assessment. IGA/I-IGA Success = Achievement of Clear (0)/Almost Clear (1) and a ≥2-grade improvement from baseline. PASI = Psoriasis Area and Severity Index. PASI-75 = 75% reduction in PASI score from baseline. PASI-100 = 100% reduction in PASI score from baseline.